HighMark Wealth Management LLC Purchases 1,100 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

HighMark Wealth Management LLC grew its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 22.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,100 shares of the biopharmaceutical company’s stock after acquiring an additional 1,100 shares during the quarter. HighMark Wealth Management LLC’s holdings in Xenon Pharmaceuticals were worth $239,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Blue Trust Inc. increased its stake in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 641 shares in the last quarter. Avior Wealth Management LLC purchased a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at $101,000. nVerses Capital LLC bought a new position in Xenon Pharmaceuticals in the 3rd quarter worth $102,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Xenon Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 487 shares in the last quarter. Finally, KBC Group NV raised its holdings in Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 780 shares during the period. Institutional investors own 95.45% of the company’s stock.

Insider Buying and Selling

In other news, CEO Ian Mortimer sold 16,315 shares of the business’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Sherry Aulin sold 18,709 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. Insiders sold 62,383 shares of company stock valued at $2,535,891 over the last 90 days. Corporate insiders own 5.52% of the company’s stock.

Xenon Pharmaceuticals Price Performance

XENE opened at $38.91 on Tuesday. The business’s fifty day simple moving average is $39.66 and its 200-day simple moving average is $40.48. Xenon Pharmaceuticals Inc. has a 12-month low of $35.53 and a 12-month high of $50.99.

Analysts Set New Price Targets

XENE has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $67.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $57.38.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.